Table 2. (A) Intraepithelial expression of CD3, CD4, CD8, CD20 and CD45RO in resected lymph nodes of LN+ NSCLC patients as predictors of disease-specific survival in the overall cohort and stratified into the SCC and ADC subgroups. (B) Multivariable models summarising significant independent prognostic factors in the total cohort and in the SCC subgroup (univariate analyses, log-rank test and Cox regression analyses, N=172, 91 and 68, respectively).
|
All |
SCC |
ADC |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | 5Y | M | HR (95%CI) | P | N (%) | 5Y | M | HR (95%CI) | P | N (%) | 5Y | M | HR (95%CI) | P | |
| A | |||||||||||||||
| CD3 | 0.875 | 0.794 | 0.608 | ||||||||||||
| <1% | 14 (8) | 30 | 29 | 1 | 9 (10) | 43 | 33 | 1 | 5 (7) | 0 | 23 | 1 | |||
| ⩾1% | 113 (66) | 30 | 24 | 1.06 (0.54–2.09) | 56 (62) | 44 | 35 | 1.13 (0.46–2.8) | 47 (69) | 17 | 24 | 0.77 (0.24–2.43) | |||
| Missing | 45 (26) | 26 (29) | 16 (24) | ||||||||||||
| CD4 | 0.209 | 0.740 | 0.097 | ||||||||||||
| <1% | 54 (31) | 39 | 25 | 1 | 29 (32) | 47 | 25 | 1 | 23 (34) | 30 | 25 | 1 | |||
| ⩾1% | 63 (37) | 21 | 27 | 1.34 (0.84–2.14) | 29 (32) | 42 | 35 | 1.12 (0.55–2.28) | 29 (43) | 0 | 21 | 1.73 (0.91–3.29) | |||
| Missing | 55 (32) | 33 (36) | 16 (24) | ||||||||||||
| CD8 | 0.277 | 0.321 | 0.410 | ||||||||||||
| ⩽5% | 37 (22) | 18 | 23 | 1 | 21 (23) | 33 | 25 | 1 | 14 (21) | 0 | 23 | 1 | |||
| >5% | 88 (51) | 33 | 21 | 0.77 (0.47–1.27) | 43 (47) | 45 | 27 | 0.71 (0.35–1.46) | 37 (54) | 21 | 21 | 0.75 (0.36–1.56) | |||
| Missing | 47 (27) | 27 (30) | 17 (25) | ||||||||||||
| CD20 | 0.681 | 0.312 | 0.954 | ||||||||||||
| <1% | 40 (23) | 29 | 25 | 1 | 21 (23) | 34 | 29 | 1 | 17 (25) | 19 | 15 | 1 | |||
| ⩾1% | 82 (48) | 30 | 24 | 0.91 (0.57–1.46) | 39 (43) | 46 | 21 | 0.71 (0.36–1.41) | 35 (51) | 16 | 24 | 1.02 (0.5–2.07) | |||
| Missing | 50 (29) | 31 (34) | 16 (24) | ||||||||||||
| CD45RO | 0.024 | 0.003 | 0.698 | ||||||||||||
| ⩽5% | 87 (51) | 20 | 19 | 1 | 45 (49) | 25 | 18 | 1 | 37 (54) | 14 | 25 | 1 | |||
| >5% | 45 (26) | 43 | 37 | 0.58 (0.37–0.9) | 21 (23) | 72 | 114 | 0.31 (0.16–0.6) | 19 (28) | 16 | 21 | 1.14 (0.58–2.22) | |||
| Missing | 40 (23) | 25 (27) | 12 (18) | ||||||||||||
| B | |||||||||||||||
| CD45RO | |||||||||||||||
| ⩽5% | 1 | 1 | |||||||||||||
| >5% | 0.58 (0.35–0.95) | 0.029 | 0.31 (0.14–0.71) | 0.006 | |||||||||||
| T stage | |||||||||||||||
| IA | 1 | ||||||||||||||
| IB | 7.42 (0.96–57.3) | 0.055 | |||||||||||||
| IIA | 8.7 (1.19–63.64) | 0.033 | |||||||||||||
| IIB | 7.12 (0.93–54.65) | 0.059 | |||||||||||||
| III | 9.89 (1.32–74.01) | 0.026 | |||||||||||||
| IV | 20.26 (2.09–196.9) | 0.010 | |||||||||||||
| Vascular infiltration | |||||||||||||||
| No | 1 | ||||||||||||||
| Yes | 1.92 (0.96–3.82) | 0.065 | |||||||||||||
Abbreviations: ADC=adenocarcinom; CD=cluster of differentiation; ECOG=Eastern Cooperative Oncology Group; HR=hazard ratio; LN=lymph node; NOS=not otherwise specified; NSCLC= non-small cell lung cancer; SCC=squamous cell carcinoma.